-
A Novel Home-based Device for Combined Occipital and Trigeminal Afferent Stimulation to Treat Depression
Linda L. Carpenter, MDDone
-
TMS Advances in Clinical Practice
Grant Hilary Brenner, MD, DFAPADone
-
Transcranial Magnetic Stimulation in Human Motor Recovery for Stroke and Spinal Cord Injury
Dylan J. Edwards, PhDDone
-
Registration
Done
-
Coffee Break
Done
-
Striatal Stimulation Recruits Bilateral Language Networks and Enhances Neural Manifold Discriminability During Swahili Learning
Nathaniel J. Killian, PhDDone
-
Poster Session
Done
-
Tuning in: Shifting from Standardized to Personalized rTMS Protocols
Juliana Corlier, PhDDone
-
Coffee Break
Done
-
Registration
Done
Optimizing TMS: Lessons from the world's largest TMS database
Neuromodulation - Advancements and Refinements
4/16/26, 10:50 AM
-
4/16/26, 11:25 AM
(US/Eastern)
(35 minutes)
Eleanor Cole, MSc PhD
Senior Director of Clinical Innovation
at Neuronetics, Inc
Eleanor Cole, MSc PhD
Senior Director of Clinical Innovation
at Neuronetics, Inc
Dr. Eleanor J. Cole is an international leader in transcranial magnetic stimulation (TMS) research, with over a decade of experience advancing neuromodulation treatments for psychiatric and neurodevelopmental disorders. Her work centers on developing and validating novel, rapid-acting TMS protocols for conditions including major depressive disorder, obsessive-compulsive disorder, autism spectrum disorder, and bipolar disorder.
Dr. Cole co-developed the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol for major depressive disorder in collaboration with Dr. Nolan Williams at Stanford University, a breakthrough recognized as a top research achievement by both the American Journal of Psychiatry and the Brain & Behavior Research Foundation. She currently serves as Senior Director of Clinical Innovation at Neuronetics, where she leads clinical research and data analytics initiatives leveraging the world’s largest TMS outcomes database to inform next-generation neuromodulation therapies.
"Transcranial magnetic stimulation (TMS) protocols comprise numerous parameters, including stimulation frequency, pulse pattern, cortical target, targeting method, intensity, session dose, pulse dose, and treatment density. The optimal treatment parameters and the interactions among these parameters remain unknown. Protocols in routine clinical use were not derived from a systematic optimization process. Instead, standard once-daily FDA-cleared protocols reflect the constraints of early devices and the design of pivotal regulatory trials. Which TMS parameters predict superior efficacy therefore remains an empirical question of considerable clinical importance.
The NeuroStar TrakStar database is the largest real-world TMS outcomes database, comprising over 170,000 patients treated across more than 1,500 clinical sites. This large sample size enables detection of parameter effects across diverse patient characteristics and clinical contexts encountered in practice. Drawing on this dataset, Dr Cole will examine the independent contributions of stimulation location, frequency, dose, and treatment density to antidepressant outcomes in major depressive disorder (MDD), alongside patient-level predictors including symptom profile, sex, and age.
The talk will conclude by identifying areas for future investigation, including the role of brain state at the time of stimulation, maintenance strategies, approaches to treatment personalization that yield clinically meaningful improvement, and the impact of concurrent pharmacological and behavioral interventions. These findings aim to provide an empirical foundation for data-driven optimization of TMS protocols.